Our BD Response to the COVID-19 Pandemic
Made for what’s next after COVID-19
BD is a purpose-driven company, advancing the world of health™ by developing medical devices and sophisticated technologies that doctors, nurses, pharmacists, researchers and caregivers rely on to improve patients’ lives. We’ve helped the world face down viral diseases for decades, from polio, smallpox and measles to HIV and the annual flu—and most recently, COVID-19.
When healthcare professionals and their patients needed a partner they could trust in the face of the greatest healthcare challenge in generations, we answered the call with a comprehensive suite of technologies and solutions essential to everything from discovery, diagnosis and treatment to preventing the spread of COVID-19. Today, the capabilities, expertise and global reach of BD are greater than ever. Our resources and relentless commitment to innovation are why we’re made for what’s next, and we’ll continue developing solutions so patients may receive exceptional care in every setting around the world.
How we addressed the most pressing challenges
The path forward out of COVID-19 relied on populations worldwide having ready access to tests.
BD remains a critical supplier of swabs and other sample collection products for COVID-19 and has launched multiple molecular tests, enabling clinicians to know if a patient currently has COVID-19. These molecular tests are primarily completed in a hospital lab versus an off-site reference lab, so the speed to result is two to three hours, not two to three days.
Our product teams developed new testing options that can be quickly deployed at scale, and we aggressively increased production of our existing portfolio to help meet the overwhelming global demand.
On any given day, our products are part of care delivery for over 90% of U.S. hospital patients.
Our technologies and devices were on the frontlines in the crisis, helping physicians, pharmacists and nurses manage medications, safely deliver drugs to patients and support advanced care needs in ICUs.
Our solutions, instruments and data analysis platforms were integral to helping researchers understand COVID-19 on a cellular level, specifically in clarifying our picture of the body’s immune system response.
With a more detailed knowledge of immune responses, researchers had a stronger foundation to develop more effective therapies.
Learn more and register for the Society of Healthcare Epidemiology in America (SHEA) infection prevention and control training course.
Enabled return to the workplace
Multifaceted testing capabilities and advanced disease monitoring capabilities were necessary to safely restart our economies.
Our information and data technologies help health systems assess data on test results, drug inventory, hospital utilization trends and more to help form a picture of risks and responses. As we look ahead to what’s next, our technologies can help detect microbiology patterns and potential outbreaks, including the possible re-emergence of COVID.
BD Track and Field Ad “Never Stopped”
65,000 people. One human hope.
COVID-19 Sample Collection
COVID-19 PCR Molecular Technology
COVID-19 Point of Care Antigen Testing
Risk of Secondary Infections in COVID-19 Patients
Infection Prevention and Control Training
Supporting COVID-19 Patients in ICUs
Tracking COVID-19 in the U.S
Supporting Research and Development of COVID-19 Treatments
Preparing for a COVID-19 Vaccination
Manufacturing
Government Partnerships
Regulatory Affairs
Partnering with Non-Government Organizations to Address COVID-19 Together
Supporting Humanitarian Organizations to Address COVID-19 Together
Serving the Community to Combat COVID-19
Supported a global community of giving
When COVID-19 challenged communities globally, BD and its associates stepped up and responded to unprecedented needs for philanthropic and volunteer support.
BD and the BD Foundation have issued nearly $2.5 million in philanthropic grants and product donations to non-profit partners that worked to protect the most vulnerable communities and individuals from the pandemic’s spread and negative impacts.
Learn about our philanthropic response: